ナルトレキソン

ナルトレキソン 化学構造式
16590-41-3
CAS番号.
16590-41-3
化学名:
ナルトレキソン
别名:
4,5α-エポキシ-3,14-ジヒドロキシ-17-(シクロプロピルメチル)モルフィナン-6-オン;17-(シクロプロピルメチル)-4,5α-エポキシ-3,14-ジヒドロキシモルフィナン-6-オン;ナルトレキソン;3,14-ジヒドロキシ-17-(シクロプロピルメチル)-4,5α-エポキシモルフィナン-6-オン;4,5α-エポキシ-3,14β-ジヒドロキシ-17-(シクロプロピルメチル)モルフィナン-6-オン;(3aR)-12-シクロプロピルメチル-2,8,9,9a-テトラヒドロ-5,9aβ-ジヒドロキシ-1H-9β,9bβ-(イミノエタノ)フェナントロ[4,5-bcd]フラン-3(3aβH)-オン;ナルトレキソン 溶液
英語名:
Naltrexone
英語别名:
Vivitrol;Um-792;C07253;en1639;en1939;trexan;Naltrel;NeMexin;celupan;Depotrex
CBNumber:
CB9394737
化学式:
C20H23NO4
分子量:
341.4
MOL File:
16590-41-3.mol

ナルトレキソン 物理性質

融点 :
168-170°
沸点 :
477.03°C (rough estimate)
比重(密度) :
1.2064 (rough estimate)
屈折率 :
1.5614 (estimate)
闪点 :
9℃
貯蔵温度 :
2-8°C
溶解性:
クロロホルム(微量)、メタノール(微量)
酸解離定数(Pka):
pKa 8.38/8.13(H2O,t =20/37,I<0.01) (Uncertain)
外見 :
個体
色:
ホワイトからライトベージュ
EPAの化学物質情報:
Naltrexone (16590-41-3)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  F,T
Rフレーズ  11-23/24/25-39/23/24/25
Sフレーズ  16-36/37-45
RIDADR  UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany  1
HSコード  2939190000
有毒物質データの 16590-41-3(Hazardous Substances Data)
毒性 LD50 in mice (mg/kg): 586 s.c. (Maickel)
絵表示(GHS) GHS hazard pictograms
注意喚起語 警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H302 飲み込むと有害 急性毒性、経口 4 警告 GHS hazard pictograms P264, P270, P301+P312, P330, P501
H336 眠気やめまいのおそれ 特定標的臓器毒性、単回暴露; 麻酔作用 3 警告 P261, P271, P304+P340, P312,P403+P233, P405, P501
注意書き
P261 粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。
P270 この製品を使用する時に、飲食または喫煙をしないこ と。
P271 屋外または換気の良い場所でのみ使用すること。
P301+P312 飲み込んだ場合:気分が悪い時は医師に連絡する こと。

ナルトレキソン 価格 もっと(7)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01TRCN285745 ナルトレキソン
Naltrexone
16590-41-3 100mg ¥70800 2024-03-01 購入
富士フイルム和光純薬株式会社(wako) W01USP1453504 ナルトレキソン
Naltrexone
16590-41-3 200mg ¥94200 2024-03-01 購入
Sigma-Aldrich Japan PHR8745 ナルトレキソン certified reference material, pharmaceutical secondary standard
certified reference material, pharmaceutical secondary standard
16590-41-3 500MG ¥38300 2024-03-01 購入
Sigma-Aldrich Japan N-007 ナルトレキソン 溶液 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
Naltrexone solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material
16590-41-3 1ml ¥3630 2024-03-01 購入
Sigma-Aldrich Japan 1453504 ナルトレキソン United States Pharmacopeia (USP) Reference Standard
Naltrexone United States Pharmacopeia (USP) Reference Standard
16590-41-3 200mg ¥55400 2024-03-01 購入

ナルトレキソン 化学特性,用途語,生産方法

効能

抗酒癖薬, 麻薬拮抗薬, オピオイド受容体拮抗薬

説明

This drug does not have agonistic properties. It is similar to naloxone in terms of pharmacological characteristics; however, it differs in two important ways—long-lasting action and that its metabolite 6-β-naltrexol is also a strong antagonist. Naltrexone is potentially hepatotoxic. Naltrexone is used for blocking pharmacological effects of opioids upon their overdose.

使用

Labeled Naltrexone, intended for use as an internal standard for the quantification of Naltrexone by GC- or LC-mass spectrometry.

定義

ChEBI: An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.

適応症

Naltrexone, an orally active opioid receptor antagonist, restores erectile function in some patients with idiopathic ED.

生物学の機能

Naltrexone (Trexan) is three to five times as potent as naloxone and has a duration of action of 24 to 72 hours, depending on the dose. It is used orally in the treatment of opioid abstinence. Naltrexone exhibits a large firstpass effect in the liver. However, the major metabolite, 6-β-naltrexol, is also a pure opioid antagonist and contributes to the potency and duration of action of naltrexone. Administration of naltrexone orally blocks the subjective effects of abused opioids and is used to decrease the craving for opioids in highly motivated recovering addicts. However, high doses of the opioids can overcome the naltrexone blockade and lead to seizures or respiratory depression and death. In addition, it has been reported recently that naltrexone can reduce the craving for alcohol in alcoholic patients. Naltrexone also has been used with success in treating apneic episodes in children, an effect hypothesized to be due to blockade of β-endorphin–induced respiratory depression.
Naltrexone can induce hepatotoxicity at doses only five times the therapeutic dose and should be used with care in patients with poor hepatic function or liver damage. Side effects of the use of naltrexone are more frequently observed than following naloxone administration. Such side effects include headache, difficulty sleeping, lethargy, increased blood pressure, nausea, sneezing, delayed ejaculation, blurred vision, and increased appetite.

一般的な説明

Naltrexone is a pure opioid antagonist at allopioid receptor subtypes with the highest affinity for theμ-receptor. Naltrexone is orally bioavailable and blocksthe effects of opiate agonists for approximately 24 hoursafter a single dose of 50 mg. It produces no opioid agonisteffects and is devoid of any intrinsic actions other thanopioid receptor blockade. Theoretically, it should workwell to treat opioid dependence but in clinical practice,patients have shown poor compliance and high relapserates. Naltrexone has also been studied to treat alcohol dependencewith mixed results. To address the complianceissues and effectively remove the “choice” of taking theantagonist, naltrexone was developed into an extendedreleaseinjectable microsphere formulation for IM injectiononce a month (Vivitrol). This formulation providessteady-state plasma concentrations of naltrexone threefoldto fourfold higher than the 50-mg oral dose 4 times aday. Currently, Vivitrol is only indicated for the treatmentof alcohol dependence. A Cochrane review found insufficientevidence from randomized controlled trials toevaluate its effectiveness for treating opioid dependence. Currently, phase II and phase III clinical trials ofan implantable pellet form of naltrexone are being conductedfor treating opioid dependence.
The CYP450 system is not involved in naltrexonemetabolism. Naltrexone is reduced to the active antagonist6-β-naltrexol by dihydrodiol dehydrogenase, a cytosolicenzyme. Naltrexone has a black box warning, because ithas the potential to cause hepatocellular injury when givenin excessive doses.

生物活性

Naltrexone is derived from oxymorphone and exhibit agonist activity only at doses that are of little clinical significance. In the absence of opioid drugs, naloxone does not cause analgesia, respiratory depression, or sedation. However, when administered with an opioid analgesic, the effects produced by the opioid agonist are promptly reversed. The ability to antagonize opioids at all of the different opioid receptors makes naloxone useful for the treatment of opioid overdose. Naltrexone has a similar profile, but it is orally active and has a significantly longer half-life.

ナルトレキソン 上流と下流の製品情報

原材料

準備製品


ナルトレキソン 生産企業

Global( 154)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Anhui Yiao New Material Technology Co., Ltd
+86-199-55145978 +8619955145978
sales8@anhuiyiao.com China 253 58
Henan Tengmao Chemical Technology Co. LTD
+8615238638457
salesvip2@hntmhg.com China 415 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21689 55
career henan chemical co
+86-0371-86658258
sales@coreychem.com China 29914 58
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49391 58
Hefei TNJ Chemical Industry Co.,Ltd.
0551-65418671
sales@tnjchem.com China 34572 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226
sales@hzclap.com CHINA 6313 58
Shaanxi Dideu Medichem Co. Ltd
+86-029-89586680 +86-18192503167
1026@dideu.com China 9126 58
Hebei Lingding Biotechnology Co., Ltd.
+86-18031140164 +86-19933155420
erin@hbldbiotech.com China 826 58

16590-41-3(ナルトレキソン)キーワード:


  • 16590-41-3
  • Um-792
  • 3,14-Dihydroxy-17-(cyclopropylmethyl)-4,5α-epoxymorphinan-6-one
  • 4,5α-Epoxy-3,14β-dihydroxy-17-(cyclopropylmethyl)morphinan-6-one
  • NALTREXONE10G
  • C07253
  • Naltrexone (base, anhydrous)
  • Naltrexone Base & HCL
  • Naltrexone (200 mg)
  • Naltrexone, 1.0 mg/mL
  • Depotrex
  • Naltrel
  • NeMexin
  • Trexonil
  • Vivitrex
  • Naltrexone Base Monohydrate
  • Morphinan-6-one,17-(cyclopropylMethyl)-4,5-epoxy-3,14-dihydroxy-, (5a)-
  • (5α)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
  • Naltrexone solution
  • en1639
  • en1939
  • NaltrexoneBase
  • Naltrexone (base and/or unspecified salts)
  • Naltrexone impurty
  • n-cyclopropylmethyl-14-hydroxydihydromorphinone
  • n-cyclopropylmethylnoroxymorphone
  • trexan
  • NALTREXONE
  • 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-morphinan-6-on
  • 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
  • 5-epoxy-3,14-dihydroxy-17-(cyclopropylmethyl)-(5-alpha)-morphinan-6-on
  • 4,5α-エポキシ-3,14-ジヒドロキシ-17-(シクロプロピルメチル)モルフィナン-6-オン
  • 17-(シクロプロピルメチル)-4,5α-エポキシ-3,14-ジヒドロキシモルフィナン-6-オン
  • ナルトレキソン
  • 3,14-ジヒドロキシ-17-(シクロプロピルメチル)-4,5α-エポキシモルフィナン-6-オン
  • 4,5α-エポキシ-3,14β-ジヒドロキシ-17-(シクロプロピルメチル)モルフィナン-6-オン
  • (3aR)-12-シクロプロピルメチル-2,8,9,9a-テトラヒドロ-5,9aβ-ジヒドロキシ-1H-9β,9bβ-(イミノエタノ)フェナントロ[4,5-bcd]フラン-3(3aβH)-オン
  • ナルトレキソン 溶液
  • 麻薬拮抗薬
Copyright 2017 © ChemicalBook. All rights reserved